Spinal Stabilization Technologies

Enrollment opened April 2017 for the NUCLEUS 161 clinical Trial in European centers. The trial will enroll 34 patients in up to 5 centers.

Spinal Stabilization Technologies product line does not have regulatory approval in any country.